GATHER trials show vision loss reduction in geographic atrophy: Analysis signals up to 59% risk reduction in rate of vision loss compared with sham treatment at 12 months.

The article reports on the results of the GATHER1 and GATHER2 trials conducted by Iveric Bio Inc. to determine the effectiveness of its avacincaptad pegol (ACP) complement C5 protein inhibitor in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Based on the exploratory time-to-event analysis, ACP is shown to be effective in reducing vision loss in the subjects. Also cited is how GA could led to vision loss and irreversible blindness.